Brochure
12 Sep 2024

LOTTE BIOLOGICS Brochure

PDF 10.2 MB

Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to contribute to a healthier world through innovative therapies. At the Syracuse Bio Campus in New York, it offers high-quality GMP manufacturing services for drug substances, with a capacity of 40,000L supported by eight 5,000L stainless steel bioreactors. The facility includes QC testing laboratories and warehouses approved by over 62 global regulatory agencies. By early 2025, LOTTE BIOLOGICS will expand into Antibody-Drug Conjugates (ADCs) conjugation services, with over $80 million invested in ADC capabilities for seamless end-to-end services.

By 2030, LOTTE BIOLOGICS is constructing three bio plants in Songdo, South Korea. The first plant, operational by 2026, will feature eight 15,000L bioreactors for commercial production and multiple 2,000L bioreactors for clinical production. Together, these facilities will offer over 360,000L of manufacturing capacity.

Content provided by our supplier

LOTTE Biologics

  • KR
  • 2022
    On CPHI since
  • 3
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO

Other Content from LOTTE Biologics ()